Highly effective treatment response and well tolerability by all oral direct acting antivirals for chronic hepatitis C patients post organ transplantation.
Immunosuppressant-related acceleration of fibrosis has been documents in chronic hepatitis C (CHC) patients who receive organ transplantation (Tx), sustained virological response (SVR) rates for these patients by pegylated interferon (IFN)-based therapy are generally poor and associated with unfavorable safety profiles. In addition IFN treatment varies by patient and poses a high risk of post-renal Tx graft rejection. This study was aimed to investigate the efficacy and safety of all oral direct acting antivirals (DAAs) for CHC patients following organ Tx. 32 organ Tx (liver: 17, kidney: 13, kidney then liver: 1, heart: 1) patients with CHC on an oral DAA (paritaprevir/ritonavir, ombitasvir and dasabuvir: 11, daclatasvir and asunaprevir: 4, sofosbuvir-based: 17) were enrolled in the study. DAAs regimen was based by genotype/subtype, patient characteristics, drug interaction profiles, and health insurance coverage. Mean patient age was 61.4±9.5 years, 50.0%, male, and 15.6% with cirrhosis. 14 (43.7%) experienced unsuccessful IFN treatment. Genotype distribution was as follows: 1a: 6, 1b: 17, 2: 7, 3: 1 and 6: 1. Mean time between Tx and DAAs therapy was 77.3±11.0 months. Baseline HCV RNA before DAAs was 6.20±0.19 log10 IU/mL. After DAAs, the distribution of week 2 HCV RNA was as follows: < 15 IU/mL (53.1%), 15 to 50 IU/mL (15.6%), 50 to 100 IU/mL (6.3%), and > 100 IU/mL (25.0%), respectively. The rates of undetectable HCV RNA (< 15 IU/mL) at week 4 and end-of-treatment were 93.8% and 100%. Subjective adverse events during therapy were generally mild, which no treatment terminations. After post-treatment follow-up, all 32 patients (100%) achieved SVR12. Highly responsive treatment and favorable tolerability were achieved by all oral DAAs in this difficult-to-treat patient population.